Australia Markets close in 4 hrs 59 mins

Why this ASX cannabis share is charging higher on Tuesday

James Mickleboro
medical marijuana, cannabis, pot, drug, medical

The MGC Pharmaceuticals Ltd (ASX: MXC) share price has been a positive performer on Tuesday.

In morning trade the cannabis company’s shares are up 3% to 3.5 cents.

Why is the MGC Pharma share price charging higher?

Investors have been buying MGC Pharma’s shares after it provided an update on its prescription growth.

According to the release, the company has seen the number of prescribed standardised, affordable cannabinoid medicines pass the 1,400 mark in Australia, the United Kingdom and Brazil. This represents 40% growth since the end of October 2019.

This has been driven by strong growth in unique patient numbers and returning patients. Over the period the company reported a 28% increase in unique patient numbers.

Management believes this further demonstrates the near-term revenue generating potential of its phytocannabinoid derived medicines.

MCG Pharma’s co-founder and managing director, Roby Zomer, was very pleased with the company’s performance in November.

He said: “We are delighted with continued momentum behind the business which is demonstrated by the ongoing growth in the number of prescriptions, increasing by 40% since the end of October, with an increasing number of return patients.”

“This shows the near-term revenue generating potential of the Company based on its phytocannabinoid derived medicines which are now available to patients in Australia, the U.K and Brazil under early access schemes. We look forward to updating the market on our further progress as we approach the New Year,” he concluded.

Cann Group rebounds.

Also on the rise in the cannabis industry on Tuesday is the Cann Group Ltd (ASX: CAN) share price. Its shares are up 11% this morning to 49.5 cents.

However, it is worth noting that its shares fell a whopping 40% on Monday. Investors have been selling its shares amid concerns over the weaker than expected demand for cannabis products in North America and the oversupply of cannabis dry flower.

Cann Group is currently constructing a massive growing facility in Victoria at significant cost. But it remains unclear whether it will be able to offload its supply given current market conditions.

The post Why this ASX cannabis share is charging higher on Tuesday appeared first on Motley Fool Australia.

NEW. Forget Pot Stocks and Buy these ASX growth Shares for 2020….

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

CLICK HERE FOR YOUR FREE REPORT!

More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019